rEVO Biotherapeutics

rEVO Biotherapeutics, a subsidiary of the LFB Group, is a biopharmaceutical company dedicated to developing and commercializing therapeutic proteins using transgenic technology. The company's flagship product, ATryn, is a recombinant form of human antithrombin and holds the distinction of being the first transgenically produced protein approved by the FDA. ATryn is indicated for the prevention of thromboembolic events in patients with hereditary antithrombin deficiency during high-risk situations like surgery or childbirth. rEVO's core technology involves the expression of complex human proteins in the milk of genetically modified goats, providing a scalable alternative to traditional bioreactor-based manufacturing. The company has also pursued clinical development of ATryn for the management of preeclampsia.